Liraglutide's efficacy as add-on therapy for Type 1 Diabetes Mellitus patients evaluated in retrospective chart review
Liraglutide as Additional Treatment in Patients With Type 1 Diabetes Mellitus
Background
Type 1 Diabetes Mellitus (T1DM) is an autoimmune condition characterized by the destruction of pancreatic beta cells, leading to absolute insulin deficiency. While insulin replacement is the cornerstone of T1DM management, patients often struggle with glycemic variability, weight gain, and increased cardiovascular risk. Glucagon-like peptide-1 receptor (GLP-1R) agonists like Liraglutide are well-established for Type 2 Diabetes Mellitus (T2DM) due to their glucose-dependent insulin secretion, glucagon suppression, gastric emptying delay, and weight loss effects. Investigating GLP-1R agonists in T1DM explores their potential to improve glycemic control and reduce insulin requirements, addressing unmet needs beyond insulin alone.